<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33655342</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.</ArticleTitle><Pagination><StartPage>3307</StartPage><EndPage>3315</EndPage><MedlinePgn>3307-3315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10495-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Edaravone was approved as a new treatment for amyotrophic lateral sclerosis (ALS), although there are different opinions on its effectiveness. Magnetic resonance (MRI) measures appear promising as diagnostic and prognostic indicators of disease. However, published studies on MRI using to monitor treatment efficacy in ALS are lacking.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The objective of this study was to investigate changes in brain MRI measures in patients treated with edaravone.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirteen ALS patients assuming edaravone (ALS-EDA) underwent MRI at baseline (T0) and after 6&#xa0;months (T6) to measure cortical thickness (CT) and fractional anisotropy (FA) of white matter (WM) tracts. MRI data of ALS-EDA were compared at T0 with those of 12 control subjects (CS), and at T6 with those of 11 ALS patients assuming only riluzole (ALS-RIL), extracted from our ALS cohort using a propensity-score-matching. A longitudinal MRI analysis was performed in ALS-EDA between T6 and T0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At T0, ALS-EDA showed a cortical widespread thinning in both hemispheres, particularly in the bilateral precentral gyrus, and a reduction of FA in bilateral corticospinal tracts, in comparison to CS. Thinning in bilateral precentral cortex and significant widespread reduction of FA in several WM tracts were observed in ALS-EDA at T6 compared to T0. At T6, no significant differences in MRI measures of ALS-EDA versus ALS-RIL were found.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients treated with edaravone showed progression of damage in the motor cortex and several WM tracts, at a six-month follow-up. Moreover, this study showed no evidence of a difference between edaravone and riluzole.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Distaso</LastName><ForeName>Eugenio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5474-8012</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milella</LastName><ForeName>Giammarco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mezzapesa</LastName><ForeName>Domenico Maria</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-5098-6379</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Introna</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3141-6442</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Errico</LastName><ForeName>Eustachio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3762-5800</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraddosio</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoccolella</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4037-7630</Identifier><AffiliationInfo><Affiliation>ASL Bari, San Paolo Hospital, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dicuonzo</LastName><ForeName>Franca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3999-6346</Identifier><AffiliationInfo><Affiliation>Neuroradiology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70100, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Isabella Laura</ForeName><Initials>IL</Initials><Identifier Source="ORCID">0000-0002-7429-3091</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy. isabellalaura.simone@uniba.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019985" MajorTopicYN="N">Benchmarking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011712" MajorTopicYN="N">Pyramidal Tracts</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Cortical thickness</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Fractional anisotropy</Keyword><Keyword MajorTopicYN="N">Longitudinal study</Keyword><Keyword MajorTopicYN="N">MRI</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33655342</ArticleId><ArticleId IdType="pmc">PMC8357666</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10495-9</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10495-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology. 2019;93(10):e984&#x2013;e994. doi: 10.1212/WNL.0000000000008063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId><ArticleId IdType="pmc">PMC6745732</ArticleId><ArticleId IdType="pubmed">31409738</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509&#x2013;527. doi: 10.1016/j.freeradbiomed.2013.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Akimoto M, Nakamura K, Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group Edaravone for treatment of early-stage ALS - Authors&#x2019; reply. Lancet Neurol. 2017;16(10):772. doi: 10.1016/S1474-4422(17)30290-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30290-9</ArticleId><ArticleId IdType="pubmed">28920878</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19) Muscle Nerve. 2020;61(2):218&#x2013;221. doi: 10.1002/mus.26740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26740</ArticleId><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna A, Gizzi M, Bello L, et al. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci. 2019;404:47&#x2013;51. doi: 10.1016/j.jns.2019.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.06.006</ArticleId><ArticleId IdType="pubmed">31325668</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):260&#x2013;263. doi: 10.1080/21678421.2019.1572191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572191</ArticleId><ArticleId IdType="pubmed">30784320</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurological Sci. 2018;11:11&#x2013;14. doi: 10.1016/j.ensci.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, Agosta F, Grosskreutz J, Filippi M, Turner MR. Neuroimaging endpoints in amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14(1):11&#x2013;23. doi: 10.1007/s13311-016-0484-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0484-9</ArticleId><ArticleId IdType="pmc">PMC5233627</ArticleId><ArticleId IdType="pubmed">27752938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro PM, Agosta F, Riva N, et al. Multimodal structural MRI in the diagnosis of motor neuron diseases. Neuroimage Clin. 2017;16:240&#x2013;247. doi: 10.1016/j.nicl.2017.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.08.002</ArticleId><ArticleId IdType="pmc">PMC5545829</ArticleId><ArticleId IdType="pubmed">28794983</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;Clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J Neurol Sci. 1994;124:96&#x2013;107. doi: 10.1016/0022-510x(94)90191-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve. 2020;61(4):508&#x2013;511. doi: 10.1002/mus.26764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26764</ArticleId><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Grachev ID, Berdichevsky D, Rauch SL, et al. A method for assessing the accuracy of intersubject registration of the human brain using anatomic landmarks. Neuroimage. 1999;9(2):250&#x2013;268. doi: 10.1006/nimg.1998.0397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.1998.0397</ArticleId><ArticleId IdType="pubmed">9927554</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage. 2010;53(4):1181&#x2013;1196. doi: 10.1016/j.neuroimage.2010.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.07.020</ArticleId><ArticleId IdType="pmc">PMC2946852</ArticleId><ArticleId IdType="pubmed">20637289</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Fischl B. Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage. 2011;57(1):19&#x2013;21. doi: 10.1016/j.neuroimage.2011.02.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.02.076</ArticleId><ArticleId IdType="pmc">PMC3260043</ArticleId><ArticleId IdType="pubmed">21376812</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61(4):1402&#x2013;1418. doi: 10.1016/j.neuroimage.2012.02.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.02.084</ArticleId><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31(4):1487&#x2013;1505. doi: 10.1016/j.neuroimage.2006.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.02.024</ArticleId><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, K&#xf6;rner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain. 2014;137(Pt 9):2546&#x2013;2555. doi: 10.1093/brain/awu162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu162</ArticleId><ArticleId IdType="pmc">PMC4132644</ArticleId><ArticleId IdType="pubmed">24951638</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007;134(5):1128&#x2013;1135. doi: 10.1016/j.jtcvs.2007.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2007.07.021</ArticleId><ArticleId IdType="pubmed">17976439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton C, Draganski B, Ashburner J, Weiskopf N. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage. 2009;48(2):371&#x2013;380. doi: 10.1016/j.neuroimage.2009.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2009.06.043</ArticleId><ArticleId IdType="pmc">PMC2741580</ArticleId><ArticleId IdType="pubmed">19559801</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009;44(1):83&#x2013;98. doi: 10.1016/j.neuroimage.2008.03.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2008.03.061</ArticleId><ArticleId IdType="pubmed">18501637</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve DN, Fischl B. False positive rates in surface-based anatomical analysis. Neuroimage. 2018;171:6&#x2013;14. doi: 10.1016/j.neuroimage12.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage12.072</ArticleId><ArticleId IdType="pmc">PMC5857431</ArticleId><ArticleId IdType="pubmed">29288131</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardoe HR, Abbott DF, Jackson GD, Initiative ADN. Sample size estimates for well-powered cross-sectional cortical thickness studies. Hum Brain Mapp. 2013;34(11):3000&#x2013;3009. doi: 10.1002/hbm.22120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.22120</ArticleId><ArticleId IdType="pmc">PMC3500581</ArticleId><ArticleId IdType="pubmed">22807270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzapesa DM, D'Errico E, Tortelli R, et al. Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS ONE. 2013;8(11):e80748. doi: 10.1371/journal.pone.0080748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080748</ArticleId><ArticleId IdType="pmc">PMC3835750</ArticleId><ArticleId IdType="pubmed">24278317</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli EG, Riva N, Rancoita PMV, et al. Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. Neuroimage Clin. 2020;27:102315. doi: 10.1016/j.nicl.2020.102315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102315</ArticleId><ArticleId IdType="pmc">PMC7327879</ArticleId><ArticleId IdType="pubmed">32593977</ArticleId></ArticleIdList></Reference><Reference><Citation>Grolez G, Moreau C, Danel-Brunaud V, et al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. 2016;16(1):155. doi: 10.1186/s12883-016-0672-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-016-0672-6</ArticleId><ArticleId IdType="pmc">PMC5002331</ArticleId><ArticleId IdType="pubmed">27567641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, Horsfield MA, Williams SC, Leigh PN. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 1999;53(5):1051&#x2013;1058. doi: 10.1212/wnl.53.5.1051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.53.5.1051</ArticleId><ArticleId IdType="pubmed">10496265</ArticleId></ArticleIdList></Reference><Reference><Citation>Maz&#xf3;n M, V&#xe1;zquez Costa JF, Ten-Esteve A, Mart&#xed;-Bonmat&#xed; L. Imaging biomarkers for the diagnosis and prognosis of neurodegenerative diseases. The example of amyotrophic lateral sclerosis. Front Neurosci. 2018 doi: 10.3389/fnins.2018.00784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00784</ArticleId><ArticleId IdType="pmc">PMC6209630</ArticleId><ArticleId IdType="pubmed">30410433</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Graaff MM, Sage CA, Caan MWA, et al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain. 2011;134(Pt 4):1211&#x2013;1228. doi: 10.1093/brain/awr016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr016</ArticleId><ArticleId IdType="pubmed">21362631</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Rocca MA, Valsasina P, et al. A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2009;80(1):53&#x2013;55. doi: 10.1136/jnnp.2008.154252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.154252</ArticleId><ArticleId IdType="pubmed">18931009</ArticleId></ArticleIdList></Reference><Reference><Citation>Keil C, Prell T, Peschel T, Hartung V, Dengler R, Grosskreutz J. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci. 2012;13:141. doi: 10.1186/1471-2202-13-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-13-141</ArticleId><ArticleId IdType="pmc">PMC3531302</ArticleId><ArticleId IdType="pubmed">23134591</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Kasper E, Machts J, et al. Longitudinal course of cortical thickness decline in amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1871&#x2013;1880. doi: 10.1007/s00415-014-7426-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7426-4</ArticleId><ArticleId IdType="pubmed">25022938</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(11):917&#x2013;924. doi: 10.1136/jnnp-2017-315573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315573</ArticleId><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MC. Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1960;23(4):269&#x2013;282. doi: 10.1136/jnnp.23.4.269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.23.4.269</ArticleId><ArticleId IdType="pmc">PMC497425</ArticleId><ArticleId IdType="pubmed">21610893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamauchi H, Fukuyama H, Ouchi Y, et al. Corpus callosum atrophy in amyotrophic lateral sclerosis. J Neurol Sci. 1995;134(1&#x2013;2):189&#x2013;196. doi: 10.1016/0022-510x(95)00220-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(95)00220-6</ArticleId><ArticleId IdType="pubmed">8747865</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. 2010;75(18):1645&#x2013;1652. doi: 10.1212/WNL.0b013e3181fb84d1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181fb84d1</ArticleId><ArticleId IdType="pmc">PMC2974368</ArticleId><ArticleId IdType="pubmed">21041787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-E, Oh JS, Sung J-J, Lee K-W, Song IC, Hong Y-H. Diffusion tensor tractography analysis of the corpus callosum fibers in amyotrophic lateral sclerosis. J Clin Neurol. 2014;10(3):249&#x2013;256. doi: 10.3988/jcn.2014.10.3.249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2014.10.3.249</ArticleId><ArticleId IdType="pmc">PMC4101103</ArticleId><ArticleId IdType="pubmed">25045379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SJ, Choi Y-H, Kwon H, et al. Sleep disturbance may alter white matter and resting state functional connectivities in Parkinson&#x2019;s disease. Sleep. 2017 doi: 10.1093/sleep/zsx009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsx009</ArticleId><ArticleId IdType="pubmed">28364425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie SJ, Dickie DA, Cox SR, et al. Brain structural differences between 73- and 92-year olds matched for childhood intelligence, social background, and intracranial volume. Neurobiol Aging. 2018;62:146&#x2013;158. doi: 10.1016/j.neurobiolaging.2017.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.10.005</ArticleId><ArticleId IdType="pmc">PMC5759896</ArticleId><ArticleId IdType="pubmed">29149632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline RP, Pirraglia E, Cheng H, et al. Surgery and Brain Atrophy In Cognitively Normal Elderly Subjects and Subjects Diagnosed with Mild Cognitive Impairment. Anesthesiology. 2012;116(3):603&#x2013;612. doi: 10.1097/ALN.0b013e318246ec0b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e318246ec0b</ArticleId><ArticleId IdType="pmc">PMC3418798</ArticleId><ArticleId IdType="pubmed">22293721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis AF, Myers M, Heiser J, Kolar M, Baird JF. Stewart JC (2020) Test-retest reliability and minimal detectable change of corticospinal tract integrity in chronic stroke. Hum Brain Mapp. 2020;41(9):2514&#x2013;2526. doi: 10.1002/hbm.24961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24961</ArticleId><ArticleId IdType="pmc">PMC7268047</ArticleId><ArticleId IdType="pubmed">32090440</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>